Polyrizon Ltd. (PLRZ): R&D Expense

Annual figures by period end, from SEC filings.

$2.13M
Year ended 2025-12-31
+83.2%
3-year compound annual growth
2022-12-31: $347.0K2023-12-31: $332.0K2024-12-31: $534.0K2025-12-31: $2.13M$2.13M
2022-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$2.13M+299.4%2026-03-25, From 2025-01-01
2024-12-31$534.0K+60.8%2026-03-25, From 2024-01-01
2023-12-31$332.0K-4.3%2026-03-25, From 2023-01-01
2022-12-31$347.0Kn/a2025-03-11, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Polyrizon Ltd. (PLRZ)2025-12-31$2.13M+299.4%
Femasys Inc (FEMY)2025-12-31$7.58M-7.8%
PolyPid Ltd. (PYPD)2025-12-31$23.81M+4.4%
Picard Medical, Inc. (PMI)2025-12-31$3.05M-9.8%
INVO Fertility, Inc. (IVF)2024-12-31$4.9K-97.1%
Co-Diagnostics, Inc. (CODX)2025-12-31$19.14M-8.8%
Vivos Therapeutics, Inc. (VVOS)2025-12-31$100.0K0.0%
Cerenome, Inc. (CNSY)2025-12-31$8.38M-20.8%
KORU Medical Systems, Inc. (KRMD)2025-12-31$4.39M-16.6%

Compare PLRZ, FEMY, PYPD, PMI side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗